共 17 条
Pulmonary marginal zone B-cell lymphoma of MALT type-What is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) Study
被引:51
作者:
Oh, Sung Yong
[1
,14
]
Kim, Won Seog
[2
]
Kim, Jin Seok
[2
]
Kim, Seok Jin
[3
]
Kwon, Hyuk-Chan
[1
,14
]
Lee, Dae Ho
[4
]
Won, Jong Ho
[5
]
Hwang, In Gyu
[6
]
Kim, Min Kyoung
[7
]
Lee, Soon Il
[8
]
Chae, Yee Soo
[9
]
Yang, Deok-Hwan
[10
]
Lee, Gyeong-Won
[11
]
Choi, Chul Won
[12
]
Park, Jinny
[13
]
Suh, Cheolwon
[4
]
Kim, Hyo-Jin
[1
]
机构:
[1] Dong A Univ, Dept Internal Med, Coll Med, Pusan 602715, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea
[3] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[4] Univ Ulsan, Dept Internal Med, Coll Med, Asan Med Ctr, Seoul, South Korea
[5] Soon Chun Hyang Univ, Univ Coll Med, Dept Internal Med, Seoul, South Korea
[6] Chung Ang Univ, Div Hematol Oncol, Dept Med, Seoul 156756, South Korea
[7] Yeungnam Univ, Coll Med, Div Oncol, Dept Internal Med, Taegu, South Korea
[8] Dankook Univ, Dept Internal Med, Coll Med, Cheonan, South Korea
[9] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Hematol Oncol, Taegu, South Korea
[10] Chonnam Natl Univ, Hwasun Hosp, Dept Hematol Oncol, Jeollanam Do, South Korea
[11] Gyeongsang Natl Univ, Coll Med, Dept Internal Med, Div Hematol Oncol, Jinju, South Korea
[12] Korea Univ, Coll Med, Div Hematol Oncol, Dept Internal Med,Anam Hosp, Seoul 136705, South Korea
[13] Gachon Med Sch, Dept Internal Med, Inchon, South Korea
[14] Dong A Univ, Coll Med, Med Res Ctr Canc Mol Therapy, Pusan, South Korea
关键词:
Pulmonary;
Marginal zone;
B-cell lymphoma;
Chemotherapy;
NON-HODGKINS-LYMPHOMA;
TISSUE BALT;
LUNG;
D O I:
10.1007/s00277-009-0875-7
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Pulmonary marginal zone B-cell lymphoma of the MALT type (P-MZL) is a relatively rare form of lymphoma. We conducted a retrospective analysis of the clinical features and treatment outcomes of P-MZL for the evaluation of prognostic factors, and to collect information about the optimal treatment modality for this condition. From 1991 to 2008, a total of 61 patients with biopsy-confirmed P-MZL were retrospectively analyzed. The median age of our subjects was 60 (range, 34-79) years. Twenty-five of the patients (41%) were initially diagnosed without any symptoms. Video-assisted thoracic surgery was utilized for diagnosis in 19 patients (31%). Thirty-eight patients' conditions (62%) involved a single lobe. Lung lesions were bilateral in 15 patients (25%). Eleven patients evidenced synchronous involvement of extra-pulmonary site MZL. Overall, 56 of 61 patients were treated with surgery (n = 22), chemotherapy (n = 28), or radiotherapy (n = 6). Among them, 46 patients achieved complete or partial remission. The median time to progression (TTP) was 5.6 (95% CI, 2.6-8.6) years. Five patients died during follow-up. Extra-pulmonary MZL and LN involvement were shown to be poor prognostic factors for TTP. We noted no differences between the operation group and chemotherapy group in terms of TTP. P-MZL tends to be an indolent disease-characterized by prolonged survival with frequent relapses. This is similar to what is observed with other cases of MALT-type site MZL. In order to conserve lung function and reduce the risks of operation, chemotherapy should be considered as a first-line option for the treatment of P-MZL.
引用
收藏
页码:563 / 568
页数:6
相关论文